Timeline

Nicolas Escriou
Permanent Researcher
02 Apr 2024
publication
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
Read more01 Apr 2023
publication
Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings
Read more01 Jan 2022
publication
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
Read more21 May 2021
publication
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.
Read more01 Jan 2021
publication
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.
Read more16 Dec 2020
publication
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
Read more02 Sep 2020
publication
A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
Read more10 Apr 2020
04 Jul 2015